TY - JOUR
T1 - A novel deletion in the GH1 gene including the IVS3 branch site responsible for autosomal dominant isolated growth hormone deficiency
AU - Vivenza, Daniela
AU - Guazzarotti, Laura
AU - Godi, Michela
AU - Frasca, Daniela
AU - Di Natale, Berardo
AU - Momigliano-Richiardi, Patricia
AU - Bona, Gianni
AU - Giordano, Mara
PY - 2006/3
Y1 - 2006/3
N2 - Context: The majority of mutations responsible for isolated GH type II deficiency (IGHD II) lead to dominant negative deleteriously increased levels of the GH1 exon 3 skipped transcripts. Objective: The aim of this study was the characterization of the molecular defect causing a familial case of IGHD II. Patients: A 2-yr-old child and her mother with severe growth failure at diagnosis (-5.8 and -6.9 SD score, respectively) and IGHD were investigated for the presence of GH1 mutations. Results: We identified a novel 22-bp deletion in IVS3 (IVS3 del+56-77) removing the putative branch point sequence (BPS). Analysis of patients' lymphocyte mRNA showed an excess exon 3 skipping. The mutated allele transfected into rat pituitary cells produced four differently spliced products: the exon 3 skipped mRNA as the main product and lower amounts of the full-length cDNA and of two novel mRNA aberrant isoforms, one with the first 86 bases of exon 4 deleted and the other lacking the entire exon 4. A mutagenized construct lacking exclusively the 7 bp of the BPS only generated the exon 4 skipped and the full-length isoforms. The presence of the full-length transcript in the absence of the canonical BPS points to an alternative BPS in IVS3. Conclusion: The IVS3 del+56-77 mutation, causing IGHD II in this family, has two separate effects on mRNA processing: 1) exon 3 skipping, analogous to most described cases of IGHD II, an effect likely caused by the reduction in size of the IVS3, and 2) partial or total exon 4 skipping, as a result of the removal of the BPS.
AB - Context: The majority of mutations responsible for isolated GH type II deficiency (IGHD II) lead to dominant negative deleteriously increased levels of the GH1 exon 3 skipped transcripts. Objective: The aim of this study was the characterization of the molecular defect causing a familial case of IGHD II. Patients: A 2-yr-old child and her mother with severe growth failure at diagnosis (-5.8 and -6.9 SD score, respectively) and IGHD were investigated for the presence of GH1 mutations. Results: We identified a novel 22-bp deletion in IVS3 (IVS3 del+56-77) removing the putative branch point sequence (BPS). Analysis of patients' lymphocyte mRNA showed an excess exon 3 skipping. The mutated allele transfected into rat pituitary cells produced four differently spliced products: the exon 3 skipped mRNA as the main product and lower amounts of the full-length cDNA and of two novel mRNA aberrant isoforms, one with the first 86 bases of exon 4 deleted and the other lacking the entire exon 4. A mutagenized construct lacking exclusively the 7 bp of the BPS only generated the exon 4 skipped and the full-length isoforms. The presence of the full-length transcript in the absence of the canonical BPS points to an alternative BPS in IVS3. Conclusion: The IVS3 del+56-77 mutation, causing IGHD II in this family, has two separate effects on mRNA processing: 1) exon 3 skipping, analogous to most described cases of IGHD II, an effect likely caused by the reduction in size of the IVS3, and 2) partial or total exon 4 skipping, as a result of the removal of the BPS.
UR - http://www.scopus.com/inward/record.url?scp=33644825661&partnerID=8YFLogxK
U2 - 10.1210/jc.2005-1703
DO - 10.1210/jc.2005-1703
M3 - Article
SN - 0021-972X
VL - 91
SP - 980
EP - 986
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 3
ER -